What is the out-of-pocket price of Margetuximab?

Margetuximab has been withdrawn from the market in China, and patients are temporarily unable to purchase it directly through domestic channels. The US version of the original drug is available overseas. The common specification is 250mg/10ml*1 bottle/box, and the price may be more than 30,000 yuan (affected by exchange rates and market fluctuations). There are currently no generic drugs on the market, so if patients want to use them, they need to obtain them through overseas channels and use them in a standardized manner in conjunction with local doctors' prescriptions and regulatory policies.

The high out-of-pocket price is mainly due to factors such as the research and development costs of monoclonal antibodies, production complexity, and import taxes and fees. The manufacturing of margetuximab involves Fc fragment optimization and high-purity protein production to ensure the stability and safety of the drug in clinical applications, which also results in a higher price. Overseas clinical guidelines show that the use of margetuximab needs to be combined with chemotherapy and follow a strict infusion regimen, all of which increase the cost of treatment.

At present, if domestic patients need to use margetuximab, they usually need to consider international medical treatment or cross-border drug purchase options, and arrange treatment under the guidance of doctors to ensure that the source of the drug is regular, safe and controllable. If domestic re-launching or approval of generic drugs occurs in the future, prices may drop, but in the short term, overseas original drugs will still be the only available channel. When patients choose treatment, they should reasonably evaluate drug benefits and costs based on economic conditions and clinical indications.

In general, margituximab has high out-of-pocket price in China and is difficult to obtain, but its clinical mechanism of action and overseas use experience still have important reference value for patients with HER2-positive breast cancer HER2-positive breast cancer. Patients and doctors need to comprehensively consider efficacy, economic burden and drug availability to formulate scientific and reasonable individualized treatment plans.

Reference materials:https://www.margenza.com/